ArticleCombinatorial chemistry & high throughput screening2026
Elucidating the Action Mechanism of Shenling Baizhu Powder in the Treatment of Ulcerative Colitis Based on Network Pharmacology and Experimental Validation.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the therapeutic mechanisms of Shenling Baizhu Powder (SLBZ) in ulcerative colitis (UC) using network pharmacology and experimental validation, assessing its potential as an alternative therapy.
methodsActive constituents and targets of SLBZ were identified using TCMSP, DrugBank, and CTD. A UC mouse model was induced with DSS and treated with SLBZ for 14 days. Histopathological changes and serum levels of IL-4, TNF-α, and HIF-1α were measured.
resultsSLBZ contained 408 active ingredients with 2118 targets, 610 of which were associated with UC. Key components included quercetin, betulin, catharanthine, and glyasperin B. Core targets were TP53, AKT1, JUN, and HSP90AA1. SLBZ modulated PI3K/Akt, JAK2/STAT3, and TNF pathways. Histological analysis showed SLBZ alleviated DSS-induced colonic tissue injury, reduced TNF-α and STAT3, and upregulated IL-4.
conclusionSLBZ targets key proteins and pathways in UC, suggesting its potential as a multitargeted therapeutic agent. Further studies are needed to validate its efficacy and safety.
Indexed as
Identifiers
40525448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.